This funding round was led by Bain Capital Life Sciences and SV Health Investors. They join existing investors, including Bill Gates and Access Biotechnology. The money will be used to support several clinical trials.
Gilead has released some early proof-of-concept data for its investigational ACC inhibitor for NASH, acquired in 2016 for $400 million and up to $800 million more in milestone payments.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.